This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sonmez, A. Articles by Ozata, M. Search for Related Content PubMed PubMed Citation Articles by Sonmez, A. Articles by Ozata, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB LOSARTAN POTASSIUM Social Bookmarking                         What's this?

Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension

Department of Internal Medicine, Gulhane School of Medicine,

Ucler Kisa

Department of Biochemistry, Kirikkale University, School of Medicine, Kirikkale, Turkey

Gokhan Uckaya

Department of Internal Medicine, Gulhane School of Medicine

Tayfun Eyileten

Department of Internal Medicine, Gulhane School of Medicine

Bilgin Comert

Department of Internal Medicine, Gulhane School of Medicine

Bayram Koc

Department of Internal Medicine, Gulhane School of Medicine

Fikri Kocabalkan

Department of Internal Medicine, Gulhane School of Medicine

Metin Ozata

Department of Endocrinology and Metabolism, Gulhane School of Medicine, Etlik-Ankara, Turkey, metinozata@ hotmail.com

Recent evidence shows that leptin may contribute to elevated blood pressure (BP) and interact with the renin-angiotensin-aldosterone and cellular immune systems. Altered T-cell activities and changes in T-cell subset ratios have also been reported in hypertension. However, little is known about the effects of AT₁-receptor antagonism on T-cell activities and plasma leptin concentrations in primary hypertension. We have, therefore, investigated the relationship between leptin and T-cell activities and the effect of an AT₁-receptor antagonist, losartan, in primary hypertension. Twenty recently-diagnosed and untreated young adults (11 males and 9 females, age; 39.9±7.6 years, range 23—49 years, BMI; 27.6±3.7 kg/m²) and 20 normotensive healthy, age-, sex- and BMI-matched controls were studied. The [³H]-thymidine uptakes of cultured lymphocytes were determined, both spontaneously and after stimulation with phytohaemagglutinin. The tests were performed before and after three months of treatment with losartan. The results indicate that the blastogenic responses of T-cells to phytohaemagglutinin are significantly higher in the patient group compared with controls (p=0.02). After normalisation of BP, T-cell responses were significantly reduced and were lower than in the controls (p=0.01). Pretreatment plasma leptin levels were significantly higher in hypertensives than in controls (p=0.01). However, losartan treatment had no significant effect on leptin concentrations; moreover, no correlation between leptin levels and T-cell activity was found. Our data show that plasma leptin levels and T-cell activity are markedly enhanced in untreated essential hypertension and that the alteration of T-cell activity is not related to plasma leptin levels. Antihypertensive treatment with losartan decreases T-cell activities but does not influence plasma leptin levels. We conclude that leptin levels are not affected by AT₁-receptor blockade and are not related to T-cell activity.

Key Words: primary hypertension • T-cell • leptin • AT1-receptor antagonism • phytohaemagglutinin

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2, 112-116 (2001)
DOI: 10.3317/jraas.2001.011


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. K. Koh, S. M. Park, and M. J. Quon Leptin and Cardiovascular Disease: Response to Therapeutic Interventions Circulation, June 24, 2008; 117(25): 3238 - 3249. [Full Text] [PDF]